CN115814004A - Medicine composition for treating bone disease - Google Patents
Medicine composition for treating bone disease Download PDFInfo
- Publication number
- CN115814004A CN115814004A CN202310017042.5A CN202310017042A CN115814004A CN 115814004 A CN115814004 A CN 115814004A CN 202310017042 A CN202310017042 A CN 202310017042A CN 115814004 A CN115814004 A CN 115814004A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- treating
- bone
- earthworm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating a lithiasis. The pharmaceutical composition for treating the lithiasis comprises 130-160 parts of angelica sinensis, 130-160 parts of earthworm, 5-7 parts of saffron and 130-160 parts of pseudo-ginseng by mass. In the prescription, 7-12 parts of borneol, 7-12 parts of pearl, 4-8 parts of cordyceps sinensis, 5-8 parts of polygala tenuifolia, 5-8 parts of ligusticum wallichii and 5-8 parts of plant oxalic acid extract are also added to enhance the treatment effect. The medicine formula of the invention can improve the microcirculation of bone tissues, has good curative effect on the osteomyelitis, changes the current situation that the osteomyelitis can not be treated by medicines, and brings good news to patients with the osteomyelitis.
Description
Technical Field
The invention belongs to the technical field of medicine preparation, and relates to a medicine composition for treating a bone disease.
Background
The osteomalacia is a developmental disorder disease, also called primary brittle sclerosis, also called marble bone, also called scleroproliferative bone disease or chalk-like bone. The disease was first discovered by Albers-Schonberg in 1904, and is called Albers-Schonberg disease. The disease is characterized by persistent calcification of cartilage and excessive deposition of calcium salt, which cause extensive hyperosteogeny and sclerosis, and has the disadvantages of ultrahigh bone mass, abnormal bone shape, prominent forehead, brittle and easily broken bone, difficult fracture healing, and complications of rickets, osteomyelitis and the like. In the worst case, the marrow cavity is closed, and the hematopoietic function of the marrow is destroyed, resulting in severe anemia. The hyperplastic bone tissue presses nerves, which causes facial paralysis, visual deterioration and blindness. Development retardation, mental dementia, stiff limbs, limited movement, inability to raise head, stand, walk or talk, deafness and extremely high death rate. The cause of the osteomalacia is not clear, and it is considered that the osteonosus is hereditary and the calcification is excessive. At present, the osteomalacia has no specific medicine, is difficult to radically cure, and can be treated symptomatically only by strengthening nursing, preventing fracture, correcting anemia, controlling infection and the like. In recent years, it has been reported that the nerve compression tissue is removed by surgery to improve the symptoms of vision or facial paralysis. However, the early stage of the disease is not easy to be detected, the disease is difficult to be treated in time, and the injury before the operation is difficult to recover and easy to recur. Nearly 10 cases of children with the stone syndrome are treated by adopting the hemopoietic stem cell transplantation in Beijing children hospital, and the prognosis of most children is good after five-year follow-up. But the matching difficulty is extremely high, the transplanting time is short, and the large-scale implementation is difficult.
As known from the related literature, the symptoms of the bone are generally divided into benign and malignant types. Benign is mostly seen in adults, also called adult type. Malignant diseases are common in infants and are also of infant type. Clinically benign is the most common. Benign patients are generally asymptomatic, often discovered by chance in cases of prolonged nonunion after the fracture. The diagnosis of the stone bone disease is mainly realized by means of a bone densitometer and an X-ray examination, and basic X-rays are represented as follows:
(1) The density of bones is increased and the bones are hardened, the trabecula becomes thick and fuzzy, the cortex is thickened, and the pulp cavity is narrow or even disappears.
(2) The middle bone is mainly found in the metacarpal and phalangeal joints, metatarsophalangeal joints, and ribs, and is a dense island with a distinct boundary.
(3) The sandwich vertebra is also called a sandwich cake, and the formation of the sandwich vertebra is characterized in that the upper and lower cartilaginous plates of the vertebral body are rich in blood vessels, so that bone deposition of the part is excessive under the condition of insufficient calcium absorption. The bone-like substance has obvious inhibiting effect on osteoclast, and the middle part of the vertebral body lacks the bone-like substance, so that the bone-like substance is eroded by the osteoclast to form high density on the upper part and the lower part of the vertebral body and low density in the middle, like a sandwich.
(4) Annual ring change of ilium. Radiolucent bands are areas of more normal bone, while dense bands present a large number of inactive osteoclasts.
(5) The skull base of the fornix of the skull is thickened and hardened, and the skull base hyperosteogeny is most obvious.
In clinical diagnosis, patients with unhealed fracture over 15 years old have high bone density, and have rough or unclear bone texture, thickened cortical bone, narrow or blocked bone marrow cavities by X-ray examination, and can be considered as benign cases of the bone stone disease. Among them, hematopoietic disorders such as multiple anemia in severe myelocoel occlusion patients belong to the overweight cases among benign patients, and the treatment difficulty is high. Malignant patients are more frequent in the infancy stage and are manifested by hypoevolutism, mental dementia, stiff limbs, limited movement, inability to raise head, stand, walk or talk, deafness, extremely high mortality rate and rare clinic. The mild patients in the malignant cases can pass through the childhood, and extend to about 12 years old, and the chances of finding the mild patients are more, which belong to the clinical common cases.
Clinical diagnosis should be distinguished from fluorosis, renal osteodystrophy, osteogenic metastasis, sclerosing disease caused by bone infection, and sclerosing osteitis deformans.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating a lithiasis.
The pharmaceutical composition for treating the lithiasis comprises 130-160 parts of angelica sinensis, 130-160 parts of earthworm, 5-7 parts of saffron and 130-160 parts of pseudo-ginseng by mass.
The pharmaceutical composition also comprises 7-12 parts of borneol, 7-12 parts of pearl and 4-8 parts of cordyceps sinensis.
The first preferred formula of the pharmaceutical composition is as follows: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 9 parts of borneol, 9 parts of pearl and 6 parts of cordyceps sinensis.
The pharmaceutical composition also comprises 5-8 parts of polygala root and 5-8 parts of ligusticum wallichii.
The preferable formula II of the pharmaceutical composition is as follows: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 6 parts of cordyceps sinensis, 9 parts of borneol, 9 parts of pearl, 6 parts of polygala tenuifolia and 7 parts of ligusticum wallichii.
The medicine composition also comprises 5-8 parts of plant oxalic acid extract.
The plant oxalic acid extract is prepared by mixing 180-200 parts by mass of spinach, 140-160 parts by mass of banana root and 150-170 parts by mass of begonia, decocting the mixture with water, filtering the mixture, and concentrating the filtrate.
The medicine formula of the invention can improve the microcirculation of bone tissues, has good curative effect on the osteomyelitis, changes the current situation that the osteomyelitis can not be treated by medicines, and brings good news to patients with the osteomyelitis.
Detailed Description
Example 1:
the formula is as follows: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron and 146 parts of pseudo-ginseng. Processing into solid preparation 4000g, and taking 4g for adult each time and 3 times daily, halving for children.
The above raw materials are illustrated as follows:
angelica Sinensis, named Radix Angelica Sinensis Sinensis of Latin school, belongs to Umbelliferae perennial herb, and the root of Angelica Sinensis is the most commonly used Chinese medicine. The water soluble components comprise ferulic acid, succinic acid, nicotinic acid, uracil, adenine, etc., and amino acids, vit B2, vit E, beta-sitosterol, linoleic acid, etc. And contains trace elements such as manganese, nickel, copper, zinc and the like. In addition, it contains polysaccharides, sucrose, volatile oil, etc. The volatile oil contains more than 40 kinds of components such as ligustilide, n-butylidenephthalide, angelone, and carvacrol. The Chinese medicine considers that the angelica has the functions of enriching blood and activating blood, regulating menstruation and relieving pain, and relaxing bowel. It is used for treating blood deficiency, sallow complexion, vertigo, palpitation, menoxenia, amenorrhea, dysmenorrhea, abdominal pain due to deficiency cold, constipation due to intestinal dryness, rheumatic arthralgia, traumatic injury, carbuncle, cellulitis, and pyocutaneous disease. The study emphasizes the function of angelica for improving microcirculation.
Earthworm, earthworm earth, also known as ricefield eel, is a representative animal of the oligochaeta of Annelida. Is one of the important Chinese medicinal materials. According to the determination, the protein content of the earthworm accounts for 53.5-65.1% of the dry weight, the fat content is about 4.4-17.38%, the carbohydrate content is about 11-17.4%, and the ash content is 7.8-23%. The earthworm body also contains vitamin D accounting for 0.04-0.073% of the fresh weight, mineral elements such as calcium and phosphorus accounting for 0.124-0.188% of the fresh weight. The earthworm contains various medicinal components such as earthworm, earthworm antitoxin, lumbrokinase, xanthine, antihistamine, vitamin B and the like. Is a nutrient source integrating protein, vitamin, mineral substances and enzyme substances. According to traditional Chinese medicine, the earthworm has the effects of clearing heat, arresting convulsion, dredging collaterals, relieving asthma and promoting urination. In recent years, the medicine is recognized in the aspects of removing tumor and treating cardiovascular and cerebrovascular diseases.
Saffron (crocus sativus L.)（The name learning: crocus sativus L.）Also known as saffron and crocus, are perennial flowers of crocus of the family iridaceae, and are also common spices. Perennial herbs. Is a rare Chinese medicinal material, has strong physiological activity, has effects of tranquilizing, eliminating phlegm, and relieving spasm, and can be used for treating gastropathy, regulating menstruation, measles, fever, jaundice, hepatosplenomegaly, etc. In clinical application, the medicine can be replaced by safflower (Latin scientific name: carthamus tinctorius L.).
Pseudo-ginseng (Latin scientific name: panax pseudo-ginseng wall. Var. Nottogynseng (Burkill) Hoo et Tseng) is a perennial herb of Panax of Araliaceae of Umbelliferae, the root of the plant is used as a medicine and contains various saponins, the total amount of which is 9.75-14.90%, and the main part is dammarane series saponin. In addition, it also contains heptanine (dencic) and a small amount of flavone as hemostatic active ingredient. Has the obvious effects of promoting blood circulation to remove blood stasis, reducing swelling and relieving pain, and the like. The study confirms that the pseudo-ginseng has the function of improving microcirculation.
Since the stone bone disease belongs to rare and difficult diseases, no uniform treatment standard exists at present. The study is divided into three indexes of effectiveness, recovery and ineffectiveness. The effective part of the method is that the fracture of the fracture patient is healed but still has fracture lines, and the walking stick is required to be used for movement; non-fractured patients have stable or decreased bone density and various symptoms are alleviated or reversed. The healing refers to the complete healing of the fracture patient and the normal action; the bone density of the non-fracture patient falls back to the normal range, various symptoms disappear, and the non-fracture patient is recovered after two years of return visit without relapse.
In 2016, the patient data of Dongcheng hospital, dongcheng health traditional Chinese medical hospital, which is the institute of bone disease of Dongcheng bone disease in Beijing, 2006-2015, are reviewed, and more than two hundred cases of fracture-nonunion patients with high bone density are found, wherein 44 cases of patients with the characteristic bone disease are found. Cure rate = 100% recovery/patient; total effective rate = (effective number + recovery number)/patient number 100%. The statistical results are as follows:
TABLE 1
| Type (B) | Patient (human) | Effective (human) | Recovery (human) | Invalid (human) | Cure rate (%) | Total effective rate (%) | Average time of administration (moon) |
| Benign | 28 | 8 | 15 | 5 | 53.4 | 82.1 | 7 |
| Malignancy | 16 | 5 | 3 | 8 | 18.8 | 50.0 | 9 |
Therefore, the formula 1 has a good treatment effect on benign osteopetrosis. The cure rate of the malignant osteomyelitis is not high, but the total effective rate is half, which shows that the traditional Chinese medicine can relieve the illness state of patients and relieve the pain, and also has therapeutic significance.
The bone disease belongs to difficult and complicated diseases, and no medicine cure report exists at present, so the clinical effect is worthy of attention. The formula has the effects of not only supplementing calcium, but also improving microcirculation, adjusting the metabolic mechanism of calcium and maintaining the dynamic balance of various components of bone tissues. For osteoporosis caused by calcium deficiency, the formula has the function of calcium supplement. For patients with hypercalcemia such as osteomalacia, the formula has the effects of promoting calcium metabolism, blocking calcium absorption and the like by dredging the blood transportation path of bone tissues.
Example 2:
the formula is as follows: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 9 parts of borneol, 9 parts of pearl and 6 parts of cordyceps sinensis. Processing into solid preparation 4500g, which is administered orally for 3 times a day, 4.5g for adult, and 60% for children.
The description of the newly added raw material medicaments:
borneol, another name: <xnotran> , , , , , , , , , . </xnotran> The main components are the resin of borneol and the crystal obtained from the volatile oil, which is close to pure dextroborneol. The resin and volatile oil of Borneolum contain various terpenoids. In addition to borneol, it also contains parthenone such as humulene, beta-elemene, caryophyllene, etc., and triterpenoid such as oleanolic acid, hordenic acid, asiatic acid, camphol ketone, coca glycol, etc. The traditional Chinese medicine believes that the traditional Chinese medicine has the effects of clearing heat, reducing swelling and relieving pain. It is commonly used to treat red heat, epidemic heat, old heat, hongchuan heat, toxic heat, erysipelas, toothache, conjunctival congestion, red and swollen throat, aphtha of the mouth and tongue, etc.
Margarita Pernulo is glossy granule formed in Margarita sac of several pearl shell family animals, and inorganic components of Margarita mainly comprise calcium carbonate and magnesium carbonate, accounting for over 91%, and silica, calcium phosphate, and Al 2 O 3 And Fe 2 O 3 And the like. The organic substance in Margarita contains 17 amino acids such as aspartic acid, threonine, serine, glutamic acid, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, arginine, and proline. In addition, it also contains more than 30 kinds of trace elements, taurine, abundant vitamins and peptides. Has the functions of delaying senility, resisting oxidation, resisting tumor, etc. and is one kind of nutrient source integrating mineral matter, amino acid and nutrients.
Cordyceps sinensis (scientific name: ophiocerdyceps sinensis (Berk.) G.H. Sung, J.M.Sung, hywel-Jones & Spataforara) is a fungus of the genus Euglena of the family Ditylenchus, which can form a complex with the larvae of hepialus armoricanus. The cordyceps sinensis is a special Chinese medicinal material and is combined with the pilose antler to be three tonic products. The main indications are sweet and neutral. Tonify kidney, benefit lung, stop bleeding and resolve phlegm. It is commonly indicated for deficiency of kidney essence, impotence, seminal emission, soreness and pain of waist and knees, chronic cough, dyspnea due to deficiency, cough due to overstrain, hemoptysis, etc. Polygala tenuifolia has effects of tranquilizing mind, improving intelligence, eliminating phlegm, and resolving stagnation. It is indicated for palpitation, amnesia, nocturnal emission, insomnia, cough with excessive phlegm, abscess, deep-rooted carbuncle, sore and swelling.
The formula is an enhanced formula of the formula in the embodiment 1, and has a better effect in clinical experiments for treating the osteopathia. For 2016, 46 cases of patients with osteodynia were treated in Beijing health-care traditional Chinese medicine hospital. The treatment criteria were the same as in example 1, and the statistical results are given in the following table:
TABLE 2
| Type (B) | Patient (human) | Effective (human) | Healing (human) | Invalid (human) | Cure rate (%) | Total effective rate (%) | Average time of administration (moon) |
| Benign | 32 | 9 | 18 | 5 | 56.3 | 84.4 | 5 |
| Malignancy | 14 | 5 | 3 | 6 | 21.5 | 57.1 | 8 |
Therefore, the formula has good treatment effect on the bone fracture.
Example 3:
the formula is as follows: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 6 parts of cordyceps sinensis, 9 parts of borneol, 9 parts of pearl, 6 parts of polygala tenuifolia and 7 parts of ligusticum wallichii. Processing into solid preparation 4500g, which is taken by adult 4.5g each time and 3 times daily, and 65% reduced for children.
Polygala tenuifolia Willd, a scientific name, is a perennial herb. Polygala tenuifolia root phloem contains saponin, and can be hydrolyzed to obtain two kinds of sapogenin crystals, polygala tenuifolia sapogenin A and Polygala tenuifolia sapogenin B. In addition, a saponin polygala tenuifolia element, namely 3-beta-glucoside of 2 beta, 27-dihydroxy-23-carboxyl oleanolic acid, is separated from the root of the plant and polygala tenuifolia of the same genus. In addition, polygala tenuifolia alcohol, N-acetylglucosamine, alkaloid tenuifoline, fatty oil, resin, etc. The fleshy root of polygala root is strong and the phloem is fleshy. It is bitter and pungent with warm property and good in property of releasing and smoothing flow of qi, and can not only induce heart qi to calm heart and induce tranquilization, but also induce kidney qi to strengthen mind without forgetting, so it is a good herb for restoring normal coordination between heart and kidney, tranquilizing mind, promoting intelligence and strengthening cognition. It can induce resuscitation and expel phlegm and saliva, so it is indicated for epilepsy, convulsions and mania due to phlegm obstruction of heart. It enters lung meridian and can dispel phlegm and relieve cough, so it is indicated for profuse and sticky phlegm, cough with difficulty in vomiting, wind-cold, cough with profuse sputum, abscess, deep-rooted carbuncle, sore and sore throat. It is good at dredging stagnation of qi and blood to resolve carbuncle and swelling, and is indicated for abscess, deep-rooted carbuncle, sore and pain of breast,
ligusticum wallichii (academic name: ligusticum chuanxiong Hort), a Chinese medicinal plant, has 40 identified components in the volatile oil of rhizome, accounting for 93.64% of the volatile oil, and has main components of ligustilide (Ligustilide) accounting for 58% and 3-butylidenephthalide (3-butylphthalide) accounting for 5.29% and sabinene (sabinene) accounting for 6.08%. Further contains butenyldinephthalide (butylidene phthalate), ligustilide (senkyunolide), neocnidilide (neocinidilide), 4-hydroxy-3-butylidenephthalide (4-hydroxy-3-butylphthalide), chuanxiong phenol (Chuanxingol), ligustilide (2, 2' -diligutilide), and 3-butyl-3, 6, 9358trihydroxy-4, 5,6, 7-tetrahydrophthalide, etc.. The nitrogen-containing compound is tetramethylpyrazine (tetramethylpyrazine, ligustrazine, chuanxinong gzine), perlyrine, trimethylamine hydrochloride, choline hydrochloride, L-isoleucyl-L-valine anhydride (L-isobutryl-L-valine anhydride), L-valyl-L-valine anhydride, 1-acetyl-beta-carboline, uracil, adenine and adenosine, and the acidic or phenolic compound is 4-hydroxy-3-methoxystyrene, 1-hydroxy-1- (3-methoxy-4-hydroxybenzene) -ethane, 4-hydroxybenzoic acid, caffeic acid, vanillic acid, ferulic acid (ferulaic acid), danamic acid (sadanic acid), rhein (chrysophanic acid), palmitic acid, vanillin and linoleic acid, in addition, the rhizome of Ligusticum wallichii contains neutral oil, which comprises pentadecane, hexadecane, heptadecane, octadecanoic acid ethyl ester, isoheptadecane, isooctadecane and methyl isoheptadecane, and also contains 5,5 '-bifurcyl ether (bis-5, 5' -formyl furyl ether), spathulenol, beta sitosterol, sucrose and a fatty glyceride. The traditional Chinese medicine considers that the ligusticum wallichii has the effects of activating blood and promoting qi, dispelling wind and relieving pain, and activating blood and removing stasis, and is suitable for various diseases caused by blood stasis; it has good effect in dispelling pathogenic wind and relieving pain, and can be used for treating headache, rheumatalgia, etc.
The formula is an enhanced formula of the formula in the embodiment 2, and has a better effect in clinical experiments for treating the stone bone disease. For 2016, 46 cases of patients with osteodynia were treated in Beijing health-care traditional Chinese medicine hospital. The treatment criteria were the same as in example 1, and the statistical results are given in the following table:
TABLE 3
| Type (B) | Patient (human) | Effective (human) | Recovery (human) | Invalid (human) | Cure rate (%) | Total effective rate (%) | Average time of administration (moon) |
| Benign | 30 | 8 | 18 | 4 | 60.0 | 86.7 | 4 |
| Malignant disease | 16 | 7 | 4 | 5 | 25.0 | 68.8 | 7 |
Therefore, the formula has good treatment effect on the bone fracture.
Example 4:
plant oxalic acid extract: 200 parts of spinach root, 150 parts of plantain root and 160 parts of begonia by weight are mixed, decocted with water, smashed and filtered to obtain juice, and then heated and concentrated into paste.
The formula 1 is as follows: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng and 6 parts of plant oxalic acid extract.
And (2) formula: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 9 parts of borneol, 9 parts of pearl, 6 parts of cordyceps sinensis and 6 parts of plant oxalic acid extract.
And (3) formula: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 9 parts of borneol, 9 parts of pearl, 6 parts of cordyceps sinensis, 6 parts of polygala tenuifolia, 7 parts of ligusticum wallichii and 6 parts of plant oxalic acid extract.
Oxalic acid, is one of the simplest organic diacids, and has the structural formula hooccoh. Oxalic acid is a metabolic product of an organism, widely distributed in plants, animals and fungi, and performs various functions in different organisms.
Oxalic acid is often considered an antagonist of mineral absorption and utilization because it reduces the bioavailability of mineral elements and readily forms insoluble calcium oxalate with calcium ions in humans. It should have a reversing effect in individuals with excessive calcium absorption. However, the oxalic acid sold on the market is harmful to human bodies, can corrode oral cavities and intestines and stomach, can cause the pH value in the human bodies to lose balance, and can influence the development of children. Therefore, the present invention uses plant oxalic acid, that is, edible oxalic acid extracted from the plant body. The oxalic acid content of the plant water extract is high because the oxalic acid is easily dissolved in water. Particularly, the paste is obtained by decocting plants such as spinach, plantain roots and begonia which are rich in oxalic acid with water, mashing, carrying out filter pressing and concentrating, and the oxalic acid content is higher. The oxalic acid of the extract can be combined with calcium in the stomach and intestine to form insoluble substances to be discharged out of the body, thereby greatly reducing calcium source and preventing calcium absorption.
The description of the newly added raw material medicaments:
spinach (Spinacia oleracea L.) is also called Portulaca oleracea, red root vegetable, psittaci, etc., and belongs to the genus spinach of Chenopodiaceae, an annual herbaceous plant. Spinach is a traditional Chinese medicine and has the effects of nourishing blood, stopping bleeding, astringing yin and moistening dryness. For epistaxis, hematochezia, scurvy, diabetes and drinking, etc., 100g spinach contains 1300 mg more oxalic acid draft, and is the plant containing the most oxalic acid.
Japanese banana root, latin, having the academic name Radix Musae, namely Japanese banana head, japanese banana, banana coke and Banana, is the rhizome of Japanese banana of the family Musaceae. The radix Musae has effects of clearing heat, quenching thirst, promoting diuresis and treating stranguria. The Chinese medicinal preparation is mainly used for treating upper respiratory diseases, urinary system diseases and diabetes, and modern researches prove that the components contained in the root of banana have a certain blood pressure reducing effect. Meanwhile, the oxalic acid-containing plant is also a plant containing more oxalic acid, and the contained oxalic acid exists in a free acid form. Other plants contain oxalic acid in the form of potassium or calcium salts, which are more favorable to the binding of calcium in the human body than free oxalic acid.
Begonia (school name: begonia grandis Dry): perennial herbaceous plants of the genus malus of the family malvaceae. Begonia is a famous ornamental flower and a traditional Chinese medicine, and the treatment effect of the Begonia is recorded in book of classical books such as Nerviliae Intermediae (Nu Shu L.) (German Hongyao (book of Germany blue-eye examination) (Dali Zi Zhi) and the like. The begonia is rich in free oxalic acid and is the main reason for the adoption of the embodiment.
The formula adopts the edible raw material medicine rich in oxalic acid, has good safety and mild action, and shows good effects of increasing curative effect and shortening treatment course.
For 2016, 43 cases of patients with osteoarthropathy were treated in prescription 3 in Beijing Jianxing Chinese medical hospital. The treatment criteria were the same as in example 1, and the statistical results are given in the following table:
TABLE 4
| Type (B) | Patient (human) | Effective (human) | Healing (human) | Invalid (human) | Cure rate (%) | Total effective rate (%) | Average time of administration (moon) |
| Benign | 28 | 7 | 17 | 4 | 60.7 | 85.7 | 4 |
| Malignancy | 15 | 6 | 5 | 4 | 33.3 | 73.3 | 6 |
Therefore, the formula has good treatment effect on the bone fracture, particularly has better curative effect on malignant patients, obviously shortens the effective time and the treatment time, and has remarkable experimental result.
Claims (7)
1. The pharmaceutical composition for treating the lithiasis is characterized by comprising 130-160 parts of angelica sinensis, 130-160 parts of earthworm, 5-7 parts of saffron and 130-160 parts of pseudo-ginseng in parts by mass.
2. The pharmaceutical composition for treating the osteomyelitis as claimed in claim 1, wherein the pharmaceutical composition further comprises 7-12 parts of borneol, 7-12 parts of pearl and 4-8 parts of cordyceps sinensis.
3. The pharmaceutical composition for treating a urolithiasis of claim 2, wherein the formulation of said pharmaceutical composition is: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 9 parts of borneol, 9 parts of pearl and 6 parts of cordyceps sinensis.
4. The pharmaceutical composition for treating a stone bone disease as claimed in claim 2, wherein the pharmaceutical composition further comprises 5-8 parts of polygala tenuifolia and 5-8 parts of ligusticum wallichii.
5. The pharmaceutical composition for treating a urolithiasis of claim 4, wherein the formulation of said pharmaceutical composition is: 146 parts of angelica sinensis, 146 parts of earthworm, 6 parts of saffron, 146 parts of pseudo-ginseng, 6 parts of cordyceps sinensis, 9 parts of borneol, 9 parts of pearl, 6 parts of polygala tenuifolia and 7 parts of ligusticum wallichii.
6. The pharmaceutical composition for the treatment of a urolithiasis according to any one of claims 1 to 5, wherein the pharmaceutical composition further comprises 5 to 8 parts of a plant oxalic acid extract.
7. The pharmaceutical composition for treating the lithiasis according to claim 6, wherein the plant oxalic acid extract is prepared by mixing 180-200 parts by mass of spinach, 140-160 parts by mass of plantain roots and 150-170 parts by mass of begonia, and then concentrating the mixture through a water decoction filtrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310017042.5A CN115814004A (en) | 2023-01-06 | 2023-01-06 | Medicine composition for treating bone disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310017042.5A CN115814004A (en) | 2023-01-06 | 2023-01-06 | Medicine composition for treating bone disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115814004A true CN115814004A (en) | 2023-03-21 |
Family
ID=85520256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310017042.5A Pending CN115814004A (en) | 2023-01-06 | 2023-01-06 | Medicine composition for treating bone disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115814004A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1531938A (en) * | 2003-03-19 | 2004-09-29 | 王璐林 | Chinese medicinal preparation for treating femoral head necrosis |
| CN101007117A (en) * | 2006-01-27 | 2007-08-01 | 贵州维康药业有限公司 | Application of 'Gu Kang' medicine in preparation of formulations for treating osteoarthritis and osteoporosis |
| CN106138506A (en) * | 2016-09-09 | 2016-11-23 | 成都市飞龙水处理技术研究所 | A kind of Chinese medicine composition treating the foster caused femur head necrosis of muscles and bones mistake |
-
2023
- 2023-01-06 CN CN202310017042.5A patent/CN115814004A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1531938A (en) * | 2003-03-19 | 2004-09-29 | 王璐林 | Chinese medicinal preparation for treating femoral head necrosis |
| CN101007117A (en) * | 2006-01-27 | 2007-08-01 | 贵州维康药业有限公司 | Application of 'Gu Kang' medicine in preparation of formulations for treating osteoarthritis and osteoporosis |
| CN106138506A (en) * | 2016-09-09 | 2016-11-23 | 成都市飞龙水处理技术研究所 | A kind of Chinese medicine composition treating the foster caused femur head necrosis of muscles and bones mistake |
Non-Patent Citations (1)
| Title |
|---|
| 刘万林等: "《激素性股骨头坏死的病因及诊疗》", 科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547750A (en) | Traditional Chinese medicine composition for treating senile osteoporosis | |
| CN104225417A (en) | Traditional Chinese medicine composition with function of assisting improvement of memory and preparation method thereof | |
| CN103877247A (en) | Medicine for treating bedsore and preparation method thereof | |
| CN103721075A (en) | Traditional Chinese medicine for use after gynecologic surgery and preparation method thereof | |
| CN102657795A (en) | Traditional Chinese medicine preparation for promoting postoperative incision healing | |
| CN117599125A (en) | A Chinese medicinal composition for supplementing calcium and strengthening bones for treating osteoporosis, and its preparation method and application | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN103156956B (en) | Blood replenishing oral liquid and preparation method thereof | |
| CN105232987A (en) | Traditional Chinese medicine promoting neurosurgery postoperative rehabilitation | |
| CN115814004A (en) | Medicine composition for treating bone disease | |
| CN112587596A (en) | Pharmaceutical composition for treating lymphatic system diseases caused by deficiency fire phlegm stagnation | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN104013728B (en) | Chinese medicine preparation of a kind of Treatment of Herpes Zoster and preparation method thereof | |
| CN104840864B (en) | A kind of Chinese medicine preparation for the treatment of infantile spleen deficiency type diarrhoea | |
| CN103933154A (en) | Traditional Chinese medicine composition for treating gout disease and preparation method thereof | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN115120690B (en) | Traditional Chinese medicine composition for treating precocious puberty and application thereof | |
| CN115737732A (en) | Medicine composition for treating compact osteitis | |
| CN102671144B (en) | Traditional Chinese medicine oral fluid for curing ronic cholecystitis and preparation method thereof | |
| CN117205273A (en) | Chinese patent medicine for resisting AIDS and preparation method thereof | |
| CN114588226A (en) | A Chinese medicinal composition for treating fracture, and its preparation method | |
| CN102671149B (en) | Brucea javanica traditional Chinese medicine oral solution for curing dysentery and preparation method | |
| CN116870072A (en) | Traditional Chinese medicine composition, application, gel and preparation method of gel | |
| CN117599147A (en) | External navel treatment preparation for treating male infertility and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |